Methotrexate Versus Apremilast for Pruritus in Psoriasis

This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality Index (DLQI) score at 8 weeks. Secondary outcomes include change in numerical rating scale for pruritus and assessment of adverse effects. The study will be conducted at Pakistan Emirates Military Hospital Rawalpindi.

NCT Number	NCT07432386
Lead Sponsor	Zarmeen Khawar
Conditions	Psoriasis, Pruritus
Enrollment	80 participants
Start Date	2026-05-14
Primary Completion	2026-10-14 (estimated)
Study Completion	2026-10-14 (estimated)
Updated on ClinicalTrials.gov	2026-05-15